GPR65 and neoplasm: However, macrophage-depleted mice with either m.CR or GPR65 KO tumors responded equivalently and fully to CAR T-cell therapy; complete remission with no tumor relapse was seen even after the depletion regimen was ended (Fig. 6E and F).